Found: 23
Select item for more details and to access through your institution.
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2024, v. 16, p. 133, doi. 10.2147/HIV.S452130
- By:
- Publication type:
- Article
Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 11, p. 955, doi. 10.1007/s40261-021-01081-y
- By:
- Publication type:
- Article
Immune response to ART initiation in advanced HIV infection.
- Published in:
- HIV Medicine, 2023, v. 24, n. 6, p. 716, doi. 10.1111/hiv.13467
- By:
- Publication type:
- Article
Long-Term HIVAIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era.
- Published in:
- Medical Decision Making, 2003, v. 23, n. 1, p. 9, doi. 10.1177/0272989X02239652
- By:
- Publication type:
- Article
Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 3, p. 1, doi. 10.1093/ofid/ofac018
- By:
- Publication type:
- Article
Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 1, p. 1, doi. 10.1093/ofid/ofab621
- By:
- Publication type:
- Article
Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 8, p. 1, doi. 10.1093/ofid/ofab363
- By:
- Publication type:
- Article
341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S181, doi. 10.1093/ofid/ofz360.414
- By:
- Publication type:
- Article
337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S179, doi. 10.1093/ofid/ofz360.410
- By:
- Publication type:
- Article
2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S862, doi. 10.1093/ofid/ofz360.2166
- By:
- Publication type:
- Article
2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S862, doi. 10.1093/ofid/ofz360.2165
- By:
- Publication type:
- Article
2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S860, doi. 10.1093/ofid/ofz360.2161
- By:
- Publication type:
- Article
978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S36, doi. 10.1093/ofid/ofz359.080
- By:
- Publication type:
- Article
Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes.
- Published in:
- BMC Infectious Diseases, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12879-023-08038-w
- By:
- Publication type:
- Article
Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
- Published in:
- Journal of the International Association of Providers of AIDS Care, 2024, p. 1, doi. 10.1177/23259582241245223
- By:
- Publication type:
- Article
Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
- Published in:
- AIDS Patient Care & STDs, 2021, v. 35, n. 11, p. 419, doi. 10.1089/apc.2021.0064
- By:
- Publication type:
- Article
Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting.
- Published in:
- Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211073235
- By:
- Publication type:
- Article
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA<sup>®</sup> observational database: a cohort study.
- Published in:
- AIDS Research & Therapy, 2019, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12981-019-0217-3
- By:
- Publication type:
- Article
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 12, p. 2807, doi. 10.1007/s40121-023-00890-2
- By:
- Publication type:
- Article
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.
- Published in:
- Infectious Diseases & Therapy, 2020, v. 9, n. 1, p. 41, doi. 10.1007/s40121-019-00274-5
- By:
- Publication type:
- Article
Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
- Published in:
- Journal of the International AIDS Society, 2021, v. 24, n. 4, p. 1, doi. 10.1002/jia2.25702
- By:
- Publication type:
- Article
HIV retention in care: results and lessons learned from the Positive Pathways Implementation Trial.
- Published in:
- BMC Primary Care, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s12875-022-01909-2
- By:
- Publication type:
- Article
Absolute Count and Percentage of CD4<sup>+</sup> Lymphocytes Are Independent Predictors of Disease Progression in HIV-Infected Persons Initiating Highly Active Antiretroviral Therapy.
- Published in:
- Journal of Infectious Diseases, 2007, v. 195, n. 3, p. 425, doi. 10.1086/510536
- By:
- Publication type:
- Article